Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 patents
10 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114112

Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma.

F T Yen, R J Deckelbaum, C J Mann, Y L Marcel, R W Milne, and A R Tall

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York 10032.

Find articles by Yen, F. in: JCI | PubMed | Google Scholar

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York 10032.

Find articles by Deckelbaum, R. in: JCI | PubMed | Google Scholar

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York 10032.

Find articles by Mann, C. in: JCI | PubMed | Google Scholar

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York 10032.

Find articles by Marcel, Y. in: JCI | PubMed | Google Scholar

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York 10032.

Find articles by Milne, R. in: JCI | PubMed | Google Scholar

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York 10032.

Find articles by Tall, A. in: JCI | PubMed | Google Scholar

Published June 1, 1989 - More info

Published in Volume 83, Issue 6 on June 1, 1989
J Clin Invest. 1989;83(6):2018–2024. https://doi.org/10.1172/JCI114112.
© 1989 The American Society for Clinical Investigation
Published June 1, 1989 - Version history
View PDF
Abstract

We have employed a neutralizing monoclonal antibody, prepared against the Mr 74,000 cholesteryl ester transfer protein (CETP), to investigate the regulation of lecithin:cholesterol acyltransferase (LCAT) activity by cholesteryl ester (CE) transfer, and also to determine which lipoproteins are substrates for LCAT in human plasma. The incubation of normolipidemic plasma led to transfer of CE from HDL to VLDL, and of triglycerides from VLDL to LDL and HDL. This net mass transfer of neutral lipids between the lipoproteins was eliminated by the monoclonal antibody. However, CE transfer inhibition had no effect on the rate of plasma cholesterol esterification in plasma incubated from 10 min to 24 h at 37 degrees C. In the absence of CE transfer, HDL and LDL exhibited cholesterol esterification activity, whereas VLDL did not. The rate of CE formation in HDL was three to four times greater than in LDL during the first hour of incubation, but CE formation in HDL decreased after 6-8 h, while that in LDL continued. Thus, (a) the Mr 74,000 CETP is responsible for all neutral lipid mass transfer in incubated human plasma, (b) the rate of CE formation in plasma is not regulated by CE transfer from HDL to other lipoproteins, and (c) HDL is the major initial substrate for LCAT; LDL assumes a more significant role only after prolonged incubation of plasma.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2018
page 2018
icon of scanned page 2019
page 2019
icon of scanned page 2020
page 2020
icon of scanned page 2021
page 2021
icon of scanned page 2022
page 2022
icon of scanned page 2023
page 2023
icon of scanned page 2024
page 2024
Version history
  • Version 1 (June 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
10 readers on Mendeley
See more details